Reuters exclusively reports U.S. criminal probe into Eli Lilly and Co - Reuters News Agency
Business & FinanceHealth

Reuters exclusively reports U.S. criminal probe into Eli Lilly and Co

Reuters exclusively reported that the U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co, focused on alleged manufacturing irregularities and records tampering at a New Jersey factory that produces the pharmaceutical giant’s COVID-19 therapy and other drugs. The probe represents a significant escalation of the government scrutiny on Lilly, which has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the factory. The Justice Department inquiry follows a Reuters report in March that a Lilly human resources officer alleged she had been forced out of her job at the factory after undertaking internal investigations of employee complaints about manufacturing lapses, falsified or destroyed records and staff shortages.

Article Tags
Topics of Interest: Business & FinanceHealth
Type: Reuters Best
Sectors: EquitiesPharmaceuticals & Healthcare
Regions: North America
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
FILE PHOTO: FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo/File Photo/File Photo
Sign up for email updates
Sign up for email updates